Cardiotoxicity of antimalarial drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or quantitative synthesis
PubMed 17646028 · doi:10.1016/S1473-3099(07)70187-1
What was done
This was a narrative clinical review evaluating the cardiotoxicity and cardiovascular effects of various antimalarial drug classes, specifically assessing electrocardiographic changes, hypotension, and confounding cardiovascular variations between acute malaria and recovery.
What was found
The abstract reports no numerical data, effect sizes, or study counts. Clinically significant cardiovascular effects were reported primarily for quinolines and structurally related agents. Multiple quinolines slightly delayed ventricular depolarization (class 1c effect, widening QRS) and exacerbated orthostatic hypotension, but only quinidine and halofantrine caused clinically significant repolarization delay (class 3 effect) and potentially dangerous QT prolongation, with halofantrine linked to sudden death. Rapid parenteral injection of chloroquine, quinine, and quinidine predictably caused hypotension; chloroquine doses of 5 mg base/kg or more by intramuscular or subcutaneous injection generated transiently hypotensive plasma concentrations. Other antimalarial classes at recommended doses showed no clinically significant cardiac effects.
Why it matters
It distinguishes genuine drug-induced cardiotoxicity—largely limited to quinidine, halofantrine, and rapid parenteral quinolines—from malaria-induced cardiovascular changes that also cause QT prolongation.
Limits
The abstract describes a narrative review without systematic search criteria, meta-analytic pooling, risk-of-bias assessment, or reported sample sizes. Quantitative event rates and safety data for amodiaquine, primaquine, and newer structurally related compounds were not established.
Cited by
- supports Antimalarial drugs can cause ventricular arrhythmias, QTc prolongation, and sudden cardiac death.